
ENDRA Life Sciences NDRA
€ 3.28
-2.55%
Quartalsbericht 2025-Q3
hinzugefügt 14.11.2025
ENDRA Life Sciences Langfristiger Schuldenstrom 2011-2026 | NDRA
Langfristiger Schuldenstrom Jährlich ENDRA Life Sciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 96.9 K | 174 K | 152 K | 132 K | 76.5 K | 66.2 K | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 174 K | 66.2 K | 116 K |
Langfristiger Schuldenstrom anderer Aktien in der Diagnostik & Forschung
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Anixa Biosciences
ANIX
|
41 K | $ 2.85 | -3.72 % | $ 92.5 K | ||
|
Centogene N.V.
CNTG
|
2.18 M | - | -6.23 % | $ 30.6 M | ||
|
Aspira Women's Health
AWH
|
77 K | - | -6.19 % | $ 10.5 M | ||
|
Celcuity
CELC
|
172 K | $ 107.62 | -0.63 % | $ 4.25 B | ||
|
Fulgent Genetics
FLGT
|
1.44 M | $ 13.82 | -2.68 % | $ 418 M | ||
|
Akumin
AKU
|
17.2 M | - | -17.87 % | $ 25.9 M | ||
|
Castle Biosciences
CSTL
|
1.66 M | $ 27.55 | -1.59 % | $ 765 M | ||
|
Heska Corporation
HSKA
|
2.94 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
475 K | - | -20.0 % | $ 1.06 M | ||
|
Charles River Laboratories International
CRL
|
57.7 M | $ 175.77 | -1.61 % | $ 8.71 B | ||
|
ICON Public Limited Company
ICLR
|
24.3 M | $ 108.44 | 0.16 % | $ 8.94 B | ||
|
IDEXX Laboratories
IDXX
|
27.1 M | $ 635.29 | -0.22 % | $ 51.1 B | ||
|
Accelerate Diagnostics
AXDX
|
829 K | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
147 K | - | - | $ 399 M | ||
|
Laboratory Corporation of America Holdings
LH
|
191 M | $ 283.19 | -1.07 % | $ 23.6 B | ||
|
Genetic Technologies Limited
GENE
|
264 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
21.5 M | - | 0.12 % | $ 80.1 M | ||
|
Lantheus Holdings
LNTH
|
3.8 M | $ 79.15 | 3.74 % | $ 5.34 B | ||
|
Motus GI Holdings
MOTS
|
169 K | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
35.1 M | $ 1 315.61 | -0.56 % | $ 27.1 B | ||
|
Biodesix
BDSX
|
719 K | $ 15.5 | -1.59 % | $ 2.01 B | ||
|
Myriad Genetics
MYGN
|
6.9 M | $ 5.26 | 4.89 % | $ 487 M | ||
|
NeoGenomics
NEO
|
4.78 M | $ 9.53 | 0.26 % | $ 1.22 B | ||
|
Biocept
BIOC
|
518 K | - | -13.05 % | $ 7.29 M | ||
|
National Research Corporation
NRC
|
2.68 M | $ 13.37 | -3.47 % | $ 328 M | ||
|
Natera
NTRA
|
7.64 M | $ 206.39 | 3.11 % | $ 20.3 B | ||
|
Invitae Corporation
NVTA
|
14.6 M | - | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
2.99 M | $ 1.12 | -1.78 % | $ 1.42 M | ||
|
Quest Diagnostics Incorporated
DGX
|
174 M | $ 208.28 | -0.95 % | $ 23.1 B | ||
|
Danaher Corporation
DHR
|
199 M | $ 204.04 | -0.9 % | $ 145 B | ||
|
Organovo Holdings
ONVO
|
521 K | - | -2.3 % | $ 19.4 M | ||
|
OPKO Health
OPK
|
12.6 M | $ 1.22 | -2.02 % | $ 847 M | ||
|
Pacific Biosciences of California
PACB
|
448 K | $ 1.51 | -7.1 % | $ 453 M | ||
|
Exact Sciences Corporation
EXAS
|
33.6 M | $ 103.38 | 0.02 % | $ 19.5 B | ||
|
Bioventus
BVS
|
4.06 M | $ 8.8 | 0.34 % | $ 551 M | ||
|
DarioHealth Corp.
DRIO
|
111 K | $ 10.3 | -4.19 % | $ 292 M | ||
|
DexCom
DXCM
|
21.6 M | $ 73.0 | -1.06 % | $ 28.5 B | ||
|
PerkinElmer
PKI
|
589 M | - | -0.91 % | $ 14.7 B | ||
|
Psychemedics Corporation
PMD
|
1.05 M | - | -1.84 % | $ 15.3 M | ||
|
Precipio
PRPO
|
218 K | $ 24.78 | 0.38 % | $ 32.2 M | ||
|
QIAGEN N.V.
QGEN
|
23.4 M | - | - | $ 10.6 B | ||
|
Quotient Limited
QTNT
|
3.45 M | - | -11.32 % | $ 1.1 M | ||
|
Illumina
ILMN
|
79 M | $ 129.9 | -2.25 % | $ 20.7 B | ||
|
Renalytix AI plc
RNLX
|
45 K | - | 5.66 % | $ 22.7 M | ||
|
VolitionRx Limited
VNRX
|
222 K | $ 0.2 | -0.74 % | $ 19.2 M |